Description:HALIFAX  Nova Scotia   BUSINESS WIRE       IMV  AntibioticDeveloper  Appili Therapeutics Acquires ATI 2307  a clinical stage antifungal program From FUJIFILM Toyama Chemical 
Title:Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical
ContentHALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a publicly traded biopharmaceutical company focused on anti-infective drug development, announced today it has signed an agreement with FUJIFILM Toyama Chemiâ€¦ [+10174 chars]
